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Abstract
Background: Women with breast cancer undergoing chemotherapy suffer from a range of detrimental disease and
treatment related side-effects. Exercise has shown to be able to counter some of these side-effects and improve
physical function as well as quality of life. The primary aim of the study is to investigate and compare the effects of
two different exercise regimens on the primary outcome cancer-related fatigue and the secondary outcomes
muscle strength, function and structure, cardiovascular fitness, systemic inflammation, skeletal muscle gene activity,
health related quality of life, pain, disease and treatment-related symptoms in women with breast cancer receiving
chemotherapy. The second aim is to examine if any effects are sustained 1, 2, and 5 years following the completion
of the intervention and to monitor return to work, recurrence and survival. The third aim of the study is to examine
the effect of attendance and adherence rates on the effects of the exercise programme.
Methods: This study is a randomised controlled trial including 240 women with breast cancer receiving
chemotherapy in Stockholm, Sweden. The participants are randomly allocated to either: group 1: Aerobic training,
group 2: Combined resistance and aerobic training, or group 3: usual care (control group). During the 5-year
follow-up period, participants in the exercise groups will receive a physical activity prescription. Measurements for
endpoints will take place at baseline, after 16 weeks (end of intervention) as well as after 1, 2 and 5 years.
Discussion: This randomised controlled trial will generate substantial information regarding the effects of different
types of exercise on the health of patients with breast cancer undergoing chemotherapy. We expect that
dissemination of the knowledge gained from this study will contribute to developing effective long term strategies
to improve the physical and psychosocial health of breast cancer survivors.
Trial registration: OptiTrain - Optimal Training Women with Breast Cancer (OptiTrain), NCT02522260; Registration:
June 9, 2015, Last updated version Feb 29, 2016. Retrospectively registered.
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Background
It is well established that exercise has the potential to im-
prove the health of cancer survivors; [1] however, evidence
is still lacking on the benefits of different modalities of ex-
ercise and different exercise prescriptions on many com-
mon disease and treatment-related side-effects. Even less
is known about the specific effects of different types of
exercise on the most commonly reported side-effect,
cancer-related fatigue [2–4]. Additionally, many existing
exercise studies have been short in duration and lack
follow-up assessments; thus, the long term-effects and
sustainability of the exercise programme are not moni-
tored or assessed. The few large randomised controlled
exercise interventions in patients with breast cancer dur-
ing chemotherapy have shown improvements in physical
function, fatigue, and health-related quality of life (QoL)
compared to patients receiving standard care [5, 6]. Differ-
ences have also been identified when comparing moderate
or vigorous to a low intensity exercise program, demon-
strating greater beneficial effects on QoL and physical
function with moderate or vigorous exercise [7]. To
develop exercise interventions and guidelines that have
the potential to address the great problems facing cancer
survivors, adequately-powered trials with long term
follow-up are urgently required.
After a cancer diagnosis and during treatment, a
marked deterioration of the individual’s physical capacity
usually ensues and it is well known that patients with
cancer generally reduce their activity levels after diagno-
sis [8]. Many patients are also forced to adapt their daily
activities [9, 10] and side-effect symptoms resulting from
treatment for cancer greatly affect the patients’ QoL.
Previous research shows that QoL is a prognostic factor
for patients with breast cancer that correlates with both
survival and how well patients respond to treatment
[11]. Although medications that target estrogen recep-
tors decrease the risk for recurrence by approximately
50%, aromatase inhibitors result in detrimental musculo-
skeletal side-effects [12], possibly due to the influence of
muscle protein turnover [13]. Other side-effects that
patients with breast cancer encounter include cardiovas-
cular complications, psychological distress [14] and
increased levels of pain [15].
Despite growing research in oncology and physical ex-
ercise there is a paucity of randomised controlled trials
that have particularly focused on investigating which
modalities of exercise are most beneficial and at which
intensity, duration and frequency these exercise modal-
ities should be prescribed to reduce the side-effects and
improve the health of patients with breast cancer [16].
While exercise trials for patients with cancer have
generally employed either resistance or aerobic exercise,
there is a lack of studies that have combined the two
training modalities [1].
Significant barriers exist for patients with cancer who
wish to return to work [17]. Exercise provides a potential
strategy to improve the physical and mental health of sur-
vivors, in turn improving their likelihood to return to
work, should they chose to. The PACES randomised clin-
ical trial demonstrated that patients who were prescribed
moderate to high intensity combined aerobic and resist-
ance exercise or were prescribed light intensity physical
activity during chemotherapy returned to work signifi-
cantly earlier and for longer hours than the standard care
group at the end of a 6-month intervention period [18].
As survival rates for breast cancer increase, facilitating
successful return to work rates is of great importance.
Attendance and adherence to exercise protocols have
generally been poorly monitored and reported in the exist-
ing literature, which may have resulted in an over- or
underestimation of the effects of exercise programs. Inves-
tigation of the importance of adhering to exercise proto-
cols and rates of attendance is warranted to understand
the real- world implications of these exercise programs.
The molecular mechanisms induced by exercise in pa-
tients with cancer are still largely unknown. Low-grade
systemic inflammation is linked to most events involved
in the development and progression of cancer [19] and
an ongoing elevated systemic inflammatory state is asso-
ciated with poor prognosis in patients with cancer [20].
Findings on anti-inflammatory effects of physical exer-
cise have mainly been demonstrated in healthy individ-
uals showing that regular exercise exerts anti-
inflammatory effects [21, 22]. Few studies have evaluated
the effects of exercise on inflammatory markers after a
cancer diagnosis and data on inflammatory responses to
exercise during chemotherapy are even scarcer but tend
to show exercise-induced anti-inflammatory effects [23,
24]. Those data are, however, confounded by heteroge-
neous patient populations, small sample sizes, and
analysis of only a few pro/anti-inflammatory biomarkers
[25]. Moreover, the effect of different types and doses of
standardised exercise on inflammatory markers in
patients with cancer need to be elucidated.
The current study will examine and compare the
effects of different modalities and intensities of exercise
on a wide range of clinically important and varying end-
points in patients with breast cancer. It will be the first
study of its kind to offer supervised exercise sessions in
the clinical setting that includes strategies to monitor
physical activity levels over the course of and after the
16-week supervised intervention period including mul-
tiple follow up measurements (1, 2, and 5 years). In
addition to functional outcomes, important biomarkers
of systemic inflammation and skeletal muscle gene activ-
ity will be assessed. This can translate into better take
out well-informed and targeted strategies for surveil-
lance and treatment of patients with breast cancer.
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The primary aim of the study is to compare the effects
of two different exercise regimens (aerobic exercise vs. a
combination of aerobic and resistance exercise) and a
usual care control group on the primary outcome cancer
related fatigue and the secondary outcomes cardiovascu-
lar fitness, muscle strength, function and structure,
systemic inflammation, gene activity, health related qual-
ity of life, pain, disease and treatment related symptoms
in patients with breast cancer receiving chemotherapy.
The second aim is to examine if these effects, if any, are
sustained one, two, and five years following the comple-
tion of the intervention and to monitor the effects of the
intervention on return to work, recurrence and survival.
The third aim of the study is to examine the effect of




This study is a 16-week randomised controlled exercise
trial with follow-up at one, two and five years. The
modified SPIRIT study flow chart is shown in Fig. 1.
Briefly, the participants are randomly allocated to either:
group 1: Aerobic exercise training (AT) twice a week for
16 weeks, group 2: Combined resistance and aerobic ex-
ercise training (CT) twice a week for 16 weeks, or group
3: usual care (UC) (control group) with physical activity
information but no supervised training. To support the
women to maintain exercising after the intervention
during the 5-year follow-up period, participants in the
exercise groups will receive a physical activity prescrip-
tion, access to public gyms and invitations to regular
motivational information seminars.
Study setting
The study centre, testing and exercise clinic are located
at Karolinska University Hospital, and Karolinska
Institutet, Stockholm, Sweden.
Ethics
Ethical permissions (with numbers 2012/1347-31/1,
2013/632-32 and 2014/408-32) have been obtained from
Fig. 1 The modified SPIRIT study flow chart
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the Regional Ethical Review Board in Stockholm. All
participants will provide informed written consent prior
to their entry into the study. In the case that changes in
the protocol are necessary, relevant amendments will be
made and submitted to the relevant ethics trial registra-
tion authorities.
Participant recruitment
Recruitment began in March 2013 and is ongoing. Two-
hundred and forty (80 in each group) women with breast
cancer undergoing chemotherapy are being recruited
from the Department of Oncology Breast and Sarcoma
units at Radiumhemmet and Södersjukhuset, Karolinska
University Hospital in Stockholm, Sweden. The expected
completion date for recruitment is August 2016. Oncol-
ogy physicians inform eligible patients about the study
and, should they wish to participate, they fill in a cardio-
vascular health questionnaire and undergo an echocar-
diogram. If no relevant cardiovascular health issues are
identified, the participants are deemed fully eligible for
the trial. Once the participants have had any of their
possible questions answered to their satisfaction and
wish to volunteer for the study, the participants then
sign the written informed consent form prior to data
collection. Research nurses at The Clinical Trials Unit at
Radiumhemmet then inform the study researchers of the
participant’s eligibility and of the group allocation of the
patient.
Eligibility criteria
Inclusion criteria include women (aged 18–70 years)
with Stage I-IIIa breast cancer about to start adjuvant
chemotherapy. Exclusion criteria are assessed by study
researchers and include patients with advanced disease,
patients where physical activity is contraindicated
because of safety reasons such as uncontrolled cardio-
vascular disease, brain or bone metastases, cognitive dys-
function, and patients who do not speak or understand
the Swedish language.
Randomisation process
The participants are randomly allocated by the Clinical
Studies Unit at Radiumhemmet, Karolinska University
Hospital (Stockholm, Sweden) to either AT, CT, or UC
at a 1:1:1 ratio using a computer-generated program. A
randomly selected subset of participants (n = 45) will
also undergo a muscle biopsy before and after the
intervention.
Blinding
As this is an exercise intervention, participants cannot
be blinded to group assignment. Outcome assessors are
not blinded to group allocation, with the exception of
assessors of muscle biopsy and blood samples who are
blinded to group allocation.
Testing
Data collection will occur prior to, directly after and at
one, two and five years following the completion of the
16-week intervention period as shown in Fig. 1. The pri-
mary outcome is fatigue. Secondary outcomes are return
to work, muscle strength and function, cardiovascular
fitness, systemic inflammation, mitochondrial density,
muscle fibre area, QoL, pain, disease status and
treatment-related symptoms.
Primary outcome
The Piper Fatigue Scale is being used to subjectively as-
sess fatigue in four dimensions: behavioral/severity,
affective meaning, sensory, and cognitive/mood [26].
The scale has been shown to have psychometric proper-
ties that are reliable for assessing subjective dimensions
of fatigue among Swedish populations of patients with
cancer [27].
Secondary outcomes
Muscle strength is being assessed by a hydraulic hand
dynamometer (JAMAR, SAEHAN corporation, Chang-
won, S. Korea), and isometric mid-thigh pull (Baseline leg
dynamometer, Fabrication Enterprises Inc., White Plains,
NY, USA) and cardiovascular fitness (predicted maximal
oxygen uptake, VO2max) is being assessed by a sub-
maximal exercise test on a cycle ergometer (Monark
928E, Monark Exercise AB, Vansbro, Sweden). Pressure
pain thresholds are assessed using a pressure algometer
(Somedic Sales AB, Hörby, Sweden). Blood sampling and
muscle biopsy procedures are taking place at the Clinical
Trial Unit laboratory at Radiumhemmet, Karolinska
University Hospital, Stockholm. Muscle biopsies (approxi-
mately 100 mg) will be obtained under local anesthesia
from the vastus lateralis muscle (lateral part of the knee
extensor muscle) with a Bergström needle [28]. This takes
place before the intervention starts and 24–72 h after the
last training session. Contractile function, markers for sys-
temic inflammation, muscle fiber area, mitochondrial
density, and expression of genes important for muscle
adaptation will be analysed. Concurrently, venous blood is
sampled for markers of systemic inflammation,
hemoglobin levels, genotyping, and for analysis of white
cell distribution and epigenetic patterns.
Patient-reported outcomes include self-reported
health-related QoL assessed by the European
Organization for Research and Treatment of Cancer
(EORTC QLQ-C30) questionnaire which is a cancer-
specific instrument that measures health-related QoL in
terms of physical, emotional, social, cognitive and every-
day function. Common cancer-related symptoms are
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assessed by the Memorial Symptom Assessment Scale
(MSAS) [29]. The instrument has been validated for
Swedish patients with breast cancer [30].
Additional measures
Additional measures include height, body mass, exercise
session attendance and adherence, haematological
parameters, cancer treatment, recurrence, survival data,
sick leave data, co-morbidities, and cause of death in
relevant registers. Sense of coherence (SOC) will also be
assessed by a questionnaire (SOC short version which
consists of 13 questions) that all participants complete
once at baseline testing [31]. The Swedish version of the
SOC-13 has been shown to have good validity and reli-
ability. It has also demonstrated high internal
consistency [32]. Participants are being asked to wear an
accelerometer (ActiGraph model GT3X+, ActiGraph
LCC, Pensacola, FL, USA) on an elastic belt over the
right hip during all waking hours, except during water
based activities for seven consecutive days directly after
baseline testing, at one, two and five years after the ini-
tial 16-week intervention to objectively record daily
activity (sedentary behaviour and physical activity)
patterns. Data will be analysed using standardised cutoff
points and valid wear-time criteria [33]. Participants will
also be asked to complete an Activity Diary to assess
daily subjective physical activity during the 16-week
intervention period.
Data entry, management and analysis
Data is collected and entered exclusively by the study re-
search staff. All hard copies of forms are kept in a locked
filing cabinet at Karolinska Institutet. Data are entered
into computer files in a re-identifiable format (partici-
pant numbers only) and password protected. Partici-
pants will not be identified in the resulting manuscripts
and reports. The data monitoring committee for the
current study is made up of the research project staff
only and does not include representatives from the fund-
ing bodies, nor will it be influenced in any way by these
funding bodies. Only the study researchers have access
to the dataset.
Confidentiality
Information collected directly from participants will be
in re-identifiable form and any information collected for,
used in or generated by this project will not be used for
any other purpose. Only the study investigators will have
access to study information.
Intervention
Phase I: Initial intervention- Supervised exercise training
Participants in the exercise groups begin training the
week after the initial testing session which takes place
prior to the patients’ second session of chemotherapy.
Both exercise groups train twice per week on non-
consecutive week days for 16 weeks. Each session is ap-
proximately 60 min in duration and is conducted at the
exercise clinic at the Karolinska University Hospital. An
exercise physiologist or oncology nurse supervises all
sessions to ensure safety, correct technique and adher-
ence to the exercise protocols. Participants can choose
to perform the continuous aerobic exercise on a cycle
ergometer, elliptical ergometer, or treadmill, the interval
aerobic exercise is performed on a cycle ergometer. Re-
sistance exercises are performed using machine resist-
ance training equipment, participants’ body weight and
free weight dumbbells and barbells. All exercise sessions
commence with a five min warm up on a cycle ergom-
eter, treadmill, or rowing machine at a rating of per-
ceived exertion (RPE) of 10–12 on the Borg scale [34]
and sessions conclude with a 10 min cool-down which
includes dynamic and static muscle stretching activities
of the major muscle groups.
Group 1 (AT) exercise sessions commence with 20
min of moderate intensity continuous aerobic exercise at
an RPE of 13–15. This is followed by 3 × 3 min bouts of
high intensity intermittent aerobic exercise at an RPE of
16–18 interspersed with ~1 min of passive or active
recovery.
Group 2 (CT) completes both resistance exercises and
high intensity intermittent aerobic exercise during each
session. The resistance training regimen consists of 8 ex-
ercises (leg press, biceps curls, triceps extensions, bench
press, shoulder press, standing row, sit ups/Russian
weighted abdominal twist, and prone lying back exten-
sions. Participants complete 2 sets of 8–12 repetitions at
an initial intensity of 70% of their estimated 1 repetition
maximum (1-RM) strength, and increase to 80% of esti-
mated 1-RM when more than 12 repetitions can be
correctly performed by the participant. Every four weeks
estimated 1-RM strength tests are performed to ensure
progression. Group 2 also completes 3 × 3 min bouts of
high intensity intermittent aerobic exercise (RPE = 16–
18) interspersed with ~1 min of passive or active
recovery.
Group 3 (UC) serves as the control group and receive
usual care for breast cancer and general information on
physical activity but no supervised exercise training or
prescription.
Phase II: Follow up - Support to maintain physical activity
after the intervention
Physical activity on prescription (PAP) is a personalised
written prescription of physical activity [35] that will be
used to support the women participating in the two ex-
ercise arms to maintain their physical activity levels
throughout the entire duration of phase II of the study.
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Participants will have the opportunity to train at the
gymnasium operator Friskis & Svettis at locations
throughout Stockholm. Motivational seminars on a
healthy lifestyle, fitness, and training options will be held
in collaboration with Friskis & Svettis three times a year
at their facility in Hagastaden, Stockholm. The research
team will be responsible for providing the motivational
seminars and physical activity prescriptions.
Statistical analyses
Data will be analysed using the IBM SPSS (Statistical
Package for the Social Sciences) 20 statistical package
for Windows (SPSS, Chicago, IL, USA). Analyses will in-
clude standard descriptive statistics (one-way ANOVAs
or Kruskall-Wallis tests, as appropriate, and Chi squared
tests). ANCOVAs accounting for baseline values will be
used for the main analysis. Variables with data that are
not normally-distributed will be log transformed prior to
ANCOVA analyses. Paired t-tests or Wilcoxon signed
rank tests, as appropriate, will be used to test for within
groups differences from baseline to follow up. All tests
will be 2-tailed and statistical significance set at p ≤ 0.05.
An intention-to-treat approach will be used for the
analyses with missing values replaced using the
expectation-maximization method.
Power Calculation: With fatigue as the primary
outcome measure, a sample size of 65 patients/group is
required, based on an effect size of 0.53 and power = 0.8.
From our research group’s experience with participant
dropout in previous exercise trials in cancer survivors,
we accounted for an attrition rate of ~20% and therefore
are aiming to recruit 80 participants into each group.
Monitoring harms
Adverse events
Study supervisors record any adverse events that occur
as a result of the testing or training activities of the
study. Participants are also asked to directly report any
adverse events they experience. Reported adverse events
are recorded by the research staff and reported both to
the relevant ethics committee and as relevant in any
subsequent publications and reports. Patients who ex-
perience an adverse event will be referred to the relevant
health professional for a medical assessment. All partici-
pants will be covered by the Patient Insurance that is
made available for participants in clinical studies at
Karolinska University Hospital.
Additional potential discomfort issues
Progressive resistance training and muscle strength test-
ing are known to result in mild discomfort, delayed on-
set muscle soreness and joint stiffness especially in
untrained individuals. However, participants are in-
formed of the possibility of delayed onset muscle
soreness, symptoms and procedures to alleviate them.
Warm-ups and cool-downs are incorporated in each
testing session to mitigate muscle soreness and return
the individual to their resting heart rate level before
leaving the training facility. There is also the risk of a
muscle strain. However, this risk is reduced by careful
monitoring of each participant, ensuring that correct
loads are used, checking technique and requiring a
warm-up and cool-down period with each exercise ses-
sion. Furthermore, all testing sessions are conducted
with one participant at a time, and exercise training
takes place in small groups of up to five participants,
each session supervised by the study exercise physiolo-
gist or oncology nurse.
There may be a low risk of falling when performing
the functional tasks; however, participants are closely
supervised. There may also be some discomfort from the
procedures involved in blood samples and muscle biop-
sies and some bruising may result. However, both proce-
dures are performed by a trained phlebotomist (blood
sample) and an experienced physician (muscle biopsy).
Discussion
This study will provide a more complete understanding
of the effects of different modalities of exercise on the
physical and mental health of breast cancer survivors in
the short and long term as well as adding further know-
ledge regarding the potential exercise may have in
managing fatigue, the most commonly reported but
poorly understood side-effect of cancer diagnosis and
treatment.
There is a concern by some health professionals and
researchers, both within and outside of the oncology set-
ting, that high intensity exercise training may not be
feasible or safe for individuals with a history of cancer.
However, recent controlled trials have adopted high in-
tensity training and showed exercise induced physical
adaptations to be superior to low or moderate intensity
exercise [18, 36] and concluded that this mode of
exercise to be safe and well tolerated in both patients
undergoing chemotherapy [18, 37] and cancer survivors
[38–40].
The results of the study will be communicated to all
participants at the conclusion of the trial. The findings
of the study will be shared with the public and research
community by way of scientific peer-reviewed publica-
tions and presentations at scientific meetings. Popular
science articles will be written to inform the public of
the study results and study findings will be communi-
cated to the relevant organisations and funding bodies
for dissemination to relevant health care and policy
professionals.
In terms of advancement of cancer survivor care, we
expect that dissemination of the knowledge gained from
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this study to contribute to developing effective strategies
to improve the physical and psychosocial health of
breast cancer survivors. In particular, we expect that the
knowledge will aid our understanding of the benefits
and issues associated with long term exercise programs.
This randomised controlled trial will generate substan-
tial information regarding the effects of different types of
exercise on the health of patients with breast cancer
undergoing chemotherapy. We anticipate that the results
of this study will help to develop future exercise programs
and interventions that are more effective and appropriate
for and attractive to patients with breast cancer.
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